This observation underscored that TF as an ablation-triggered target pool at the ablation area boundary post-PEI facilitates delivery of 177Lu-DOTA-tTF to the interface between the ablation area and residual tumor, synergistically eliminating M2 macrophages and residual tumor cells. The gene discussed is TF; the disease is neoplasm.